State Board of Medical Examiners

Notice to Physician Assistants

Notice; Physician Assistants—Act 453 of the 2015 Session of the Louisiana Legislature amended the law governing physician assistants (PAs) to include, among other items, Schedule II CDS within the drugs that could be delegated to a PA by a supervising physician (SP). A rule-making effort to conform the Board’s existing rules to the changes is in development. In the interim, the law supersedes the rules where there is a disparity. A PA whose SP wishes to delegate Schedule II authority should complete and return to the Board an updated Notice of Intent to practice (available on this website).



Underreporting of Infectious Diseases

Recent outbreaks of viral meningitis and salmonella in Louisiana have the state’s Infectious disease epidemiology department concerned about the underreporting of certain infectious diseases.  While many of these conditions do get reported to them from labs or the infection control department of hospitals, we would like to remind health practitioners of their individual responsibility in this matter. 

Dr. Raoult Ratard, the state epidemiologist realizes that physicians and others are busy professionals and will not report every case of infectious disease.  However, he and his associates in the department of infectious disease epidemiology do hope that health professionals use their common sense.  If, for example, a physician, nurse or PA sees a child with diarrhea and bloody stool and it is mentioned that various children in the class are suffering from the same condition, a call to the hotline is in order.  The faster the department is made aware of a potential problem, the faster it can operate to locate the source of a food borne illness or a dangerous respiratory or other condition and prevent further morbidity and/or mortality.

For further information on what diseases are reportable under the Sanitary Code and how soon they must be reported after diagnoses, go to and download this helpful information.  (You may want to post this one page document in your office.) The 24 hour hotline number to report infectious diseases or suspected outbreaks is 800-256-2748.


Guidance For Physicians On Safe Purchase Of Drugs From Pharmaceutical Distributors

 GUIDANCE FOR PHYSICIANS ON SAFE PURCHASE OF DRUGS FROM PHARMACEUTICAL DISTRIBUTORS Health care providers can help protect the public health and reduce potential legal liability by avoiding purchasing prescription drugs that do not comply with U.S. regulatory requirements.  To help ensure safe drug purchasing from pharmaceutical distributors, FDA recommends that health care providers and their staff do the following:

  1. Ensure you receive FDA-approved prescription Drugs.Buying directly from the manufacturer or a wholesale drug distributor licensed in your state will reduce the chances of unsafe of ineffective drugs reaching your patients. (check if state-approved at
  2. Beware of offers too good to be true.Aggressive marketing tactics and deep discounts on prescription drugs may indicate the products are stolen, counterfeit, substandard or unapproved
  3. Buy only from state-licensed wholesale drug distributors.
  4. Caution:check for these signs that a prescription may be unsafe, ineffective or fake:
    1. Label is not in English
    2. Packaging looks slightly different from the FDA approved product
    3. Product name differs from the name of the FDA approved drug
    4. Dosing recommendations are unfamiliar
    5. Safety information or warnings are missing
    6. Dosage form or administration is different
  5. Pay close attention to patient feedback.If several patients report that they are experiencing a new side effect or lack of therapeutic effect form the same product, consider that the drug may be substandard or counterfeit.Health care providers and patients are encourages to report any adverse events or suspect medication to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program either online at or by calling 1-800-332-1088.


Purchasing Safe Drugs and Devices from an Approved Source




Under the Drug Supply Chain Security Act (21 U.S.C. 351 et seq.), as of January 1, 2015, all healthcare providers who dispense or administer prescription drugs to patients are required to purchase their prescription drug products only from authorized trading partners licensed by or registered with the state or federal government. This will help protect patients from being harmed by potentially dangerous and illegal drug products.


The FDA is committed to promoting and protecting the public health by helping to ensure that only safe, effective, and high-quality drugs and devices are available to the American public. Health care providers and patients are encouraged to report any suspicious medical products to FDA's Office of Criminal Investigations Physician offices should be wary of mass advertising campaigns via “blast faxes,” phone calls, direct email, and online marketing for the sale of physician administered drugs and injections.


The Louisiana Board of Wholesale Drug Distributors (LBWDD) is the state agency charged with the responsibility to safeguard life and health and to promote the public welfare by licensing and regulating all entities engaged in the wholesale distribution of controlled or legend drugs or devices in/into the state of Louisiana.


To verify that a vendor you buy drugs or devices from is licensed by the LBWDD, go to:



Electronic Prescribing of Controlled Substances

Prescribers:  Please read the following to be properly informed about electronic prescribing of CDS:

Since June 1, 2010, the DEA has allowed electronic prescribing of controlled substances.  However, the electronic transmission of controlled substance prescriptions is not mandatory in Louisiana.

Paper prescriptions for all schedule II-V controlled substances are still permitted.  Telephone authorization for schedules III-V controlled substances are still valid.

Electronic prescriptions for controlled substances, including schedule II, are permitted only when both of the following criteria are met:

1. The prescriber’s software has been authenticated by a DEA–approved certifying organization; and

2. The pharmacy’s software has been authenticated by a DEA-approved certifying organization.

For a list of DEA-approved certifying organizations, go to:

Not all prescribers or pharmacies have approved systems.  Prescribers and pharmacies should understand the capabilities and limitations of their current software.   For more information on the various e-prescribing software vendors and their attributes, the LA Board of Pharmacy recommends the following website:

Physicians should ensure that their prescribing software is approved for this purpose by one of the entities on the DEA certified list above.  In some cases, this may only require an upgrade of the software you are already using.  In the absence of approved software, CDS prescriptions transmitted electronically to a pharmacy are deemed to be “faxed” and will not be filled without an original signature.

Prescribers MUST:

1. Have a certification report for the electronic health records (EHR) or electronic prescription application to verify compliance with the DEA rule.

2. Obtain digital “credentials” to electronically sign CDS prescriptions.The prescriber may need to contact the EHR or application provider to determine how to obtain these credentials.

3. Restrict access so that only authorized individuals may electronically “sign” CDS prescriptions.

For further information please review the information available on the DEA website at:



Alert for Measles in Louisiana and Report Suspected Cases

02/03/2015 02:50:04 PM
Message Severity: HIGH

This is a message from the Louisiana Department of Health and Hospitals Emergency Operations Center (DHH EOC). To remain current on newly released information about the recent national measles outbreak, visit the Centers for Disease Control and Prevention (CDC) website at .

The Department of Health and Hospitals (DHH) and CDC encourages healthcare providers to consider measles when evaluating a patient with febrile rash and ask about a patient's vaccine status, recent travel history, and contact with individuals who have febrile rash illness.

Measles can be prevented with the MMR (measles, mumps, and rubella) vaccine. In the United States, widespread use of measles vaccine has led to a greater than 99% reduction in measles cases compared with the pre-vaccine era. For additional information on measles vaccination, visit the CDC website at .

Also, please see the letter attached for additional information on measles signs and symptoms and reporting suspected cases.

By Louisiana statue, measles must be reported immediately upon suspicion. Please report suspected measles cases promptly to the Louisiana Office of Public Health Immunization Program at 504-838-5300 or Louisiana Epidemiology Hotline 800-256-2748 after hours.